

Rising Autoimmune Disorders Fuels Tumor Necrosis Factor Inhibitor Drugs Market, Set to Reach \$43 Billion by 2027

The Business Research Company's Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032

LANDON, GREATER LONDON, UK, November 10, 2023 /EINPresswire.com/ -- The [global tumor necrosis factor inhibitor drugs market](#) is set to expand

“

The global tumor necrosis factor inhibitor drugs market size is expected to grow from \$41.23 billion in 2022 to \$41.84 billion in 2023 at a compound annual growth rate (CAGR) of 1.5%.”

The Business Research Company

steadily, with a projected increase from \$41.23 billion in 2022 to \$41.84 billion in 2023, demonstrating a Compound Annual Growth Rate (CAGR) of 1.5%. Despite challenges posed by the Russia-Ukraine conflict and the persisting impact of the COVID-19 pandemic, the market is anticipated to reach \$43.88 billion by 2027, maintaining a moderate CAGR of 1.2%.

Impact of Rising Autoimmune Illnesses on Market Growth

The accelerated growth of the tumor necrosis factor inhibitor drugs market is primarily attributed to the mounting prevalence of autoimmune disorders. These conditions occur when the body's immune system inadvertently attacks and damages healthy tissues. Tumor necrosis factor inhibitor drugs are employed in the treatment of autoimmune disorders to curb inflammation, providing relief from pain, swelling, and other associated symptoms. Notably, data from the Autoimmune Association reveals that 4.7 million men in the United States suffered from autoimmune diseases in 2022, representing 20% of all autoimmune disease patients. With an estimated 31 million people in the US affected by 80-150 distinct autoimmune diseases, this figure is projected to increase in the coming years, thereby driving the growth of the tumor necrosis factor inhibitor drugs market.

For Comprehensive Insights into the Global Tumor Necrosis Factor Inhibitor Drugs Market, Refer to the sample Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=9383&type=smp>

Market Segments:

- By Product Type: Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars
- By Route Of Administration: Subcutaneous Injection, Intravenous Injection
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- By Application: Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Other Applications

Product Innovations Drive Market Growth

Leading companies such as Pfizer Inc. and Samsung Biologics are actively contributing to product innovations within the tumor necrosis factor inhibitor drugs market. Pfizer's launch of XELJANZ, designed to treat ankylosing spondylitis in patients unresponsive to one or more TNF blockers, offers a unique treatment option that does not necessitate injections or infusions. Meanwhile, Samsung Biologics' acquisition of Samsungbioepis Co. Ltd. for \$2.3 billion is expected to bolster the former's biosimilar development capabilities and drive performance in novel drug development.

North America Dominates, Asia-Pacific Emerges as the Fastest-Growing Region

In 2022, North America captured the largest share in the tumor necrosis factor inhibitor drugs market, while the Asia-Pacific region is poised to witness the most rapid growth during the forecast period, presenting lucrative opportunities for the global tumor necrosis factor (TNF) inhibitors drugs market.

For an In-Depth Analysis of the Global Tumor Necrosis Factor Inhibitor Drugs Market, Access the Complete Report:

<https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report>

[Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2023](#) from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan,



Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2023 by The Business Research Company is the most comprehensive report that provides insights on tumor necrosis factor inhibitor drugs market size, tumor necrosis factor inhibitor drugs market drivers and trends, tumor necrosis factor inhibitor drugs market major players, tumor necrosis factor inhibitor drugs market competitors' revenues, tumor necrosis factor inhibitor drugs market positioning, and tumor necrosis factor medications market growth across geographies. The tumor necrosis factor inhibitor drugs market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Tumor Ablation Therapy Devices Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/tumor-ablation-therapy-devices-global-market-report>

Tumor Embolization Devices Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report>

Solid Tumor Cancer Treatment Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market->

[About The Business Research Company](#)

The Business Research Company has published over 3000+ detailed industry reports, spanning over 3000+ market segments and 60 geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

Facebook: <https://www.facebook.com/TheBusinessResearchCompany>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ

Blog: <https://blog.tbrc.info/>

Healthcare Blog: <https://healthcareresearchreports.com/>

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/665528203>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.